{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:49:57Z","timestamp":1794433797955,"version":"4.9.1"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T00:00:00Z","timestamp":1301011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The platelet contribution to the thrombophilic state of patients with myeloproliferative neoplasms (MPNs), i.e., essential thrombocythemia (ET) and polycythemia vera (PV), remains uncertain. In this study we aimed to characterize the thrombin generation (TG) potential expressed by platelets from these subjects, compare it to normal platelets, and identify what factors might be responsible for platelet TG. In a group of 140 MPN patients (80 ET and 60 PV) and 72 healthy subjects we measured the global procoagulant potential of platelet rich plasma (PRP) utilizing the TG assay by the calibrated automated thrombogram (CAT). To characterize the procoagulant contribution of platelets in PRP, the TG of both isolated platelets and platelet poor plasma was measured, and the platelet surface expression of TF was determined. Finally, the activation status of platelets was assessed by the levels of P\u2010selectin expressed on platelet surface. MPN patients had significantly increased PRP and isolated platelet TG potential compared to controls. This was associated to the occurrence of platelet activation. Patients carriers of the <jats:italic>JAK2V617F<\/jats:italic> mutation showed the highest values of TG and platelet surface TF and P\u2010selectin. Platelet TG potential was significantly lower in hydroxyurea (HU) compared to non\u2010HU\u2010treated patients and was lowest in HU\u2010treated <jats:italic>JAK2V617F<\/jats:italic> carriers. In subjects not receiving HU, platelet TG significantly increased by <jats:italic>JAK2V617F<\/jats:italic> allele burden increment (<jats:italic>P<\/jats:italic> &lt; 0.05). This study demonstrates a platelet\u2010dependent form of hypercoagulability in MPN patients, particularly in those carriers of the <jats:italic>JAK2V617F<\/jats:italic> mutation. The cytoreductive therapy with HU significantly affects this prothrombotic phenotype. Am. J. Hematol. 86:337\u2013342, 2011. \u00a9 2011 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21974","type":"journal-article","created":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T16:41:25Z","timestamp":1294245685000},"page":"337-342","source":"Crossref","is-referenced-by-count":84,"title":["Platelet\u2010induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera"],"prefix":"10.1002","volume":"86","author":[{"given":"Marina","family":"Panova\u2010Noeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri Maria","family":"Spronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Diani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Good","family":"Finazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Salmoiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aueesandrd","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titiano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huao","family":"Ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2003.1.200"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05277.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.33756"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046342"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-042515"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07258.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2009.02.004"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(94)00164-O"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02886685","article-title":"Spectrum of platelet aggregation abnormalities in myeloproliferative diseases","volume":"11","author":"Cortelazzo S","year":"1981","journal-title":"Ric Clin Lab"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996114"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02030.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.409"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2005.01.015"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.01.053"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.05.023"},{"key":"e_1_2_5_17_2","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano\u2010Rodrigo E","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613209"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000031340.68494.34"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-07-0408"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083501"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199804)57:4<277::AID-AJH2>3.0.CO;2-R"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164087"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1159\/000071642"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21266"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11460"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237719"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21338"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2009.03.003"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.177"},{"key":"e_1_2_5_31_2","first-page":"261","article-title":"Safety profile of hydroxyurea in the treatment of patients with Philadelphia\u2010negative chronic myeloproliferative disorders","volume":"90","author":"Randi ML","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12801"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02194.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-09-0663"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-11-0764"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.08.011"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.09.005"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10634"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22663"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/09537100600758677"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21974","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:43:24Z","timestamp":1700556204000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,25]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1002\/ajh.21974"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21974","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,25]]}}}